Novavax, Inc. (NVAX) announced that the U.S. FDA has granted expanded emergency use authorization for Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) for active immunization to prevent COVID-19 in adolescents aged 12 through 17. The company specified that Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Doses of the Novavax COVID-19 Vaccine, Adjuvanted are available for use in adolescents upon the CDC's recommendation, the company noted.
In July 2022 the U.S. FDA had granted EUA for a two-dose primary series in adults aged 18 and older, followed by a recommendation from the CDC Advisory Committee on Immunization Practices, and endorsement from the CDC.
For comments and feedback contact: editorial@rttnews.com
Business News